Loading company…
Semathera develops biological traps that target SEMA3A to treat diabetic retinopathy and related retinal diseases.
Semathera Inc., founded in 2016 and based in Montreal, Canada, is a biopharmaceutical company developing biological traps that bind SEMA3A and other cytokines implicated in diabetic retinopathy. Its revenue model relies on partnerships and licensing with pharmaceutical companies. The company has received USD 2.6 mn in total funding, most recently in a deal on March 21, 2018 co-led by AmorChem and Senju Pharmaceutical Co., Ltd. It is at the Seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in